Chronic inflammatory demyelinating polyneuropathy (CIDP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Chronic inflammatory demyelinating polyneuropathy (CIDP)

Chronic inflammatory demyelinating polyneuropathy (CIDP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder in which there is inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering (myelin sheath) over the nerves. The exact cause of CIDP is unknown but there are strong indications that CIDP is an autoimmune disorder.

Thelansis Epidemiology study indicates CIDP affects males twice as often as females (M2:F1) and the average age of onset is 50. The prevalence of CIDP is estimated to be around 5-7 cases per 100,000 individuals.

Competitive landscape of CIDP includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of CIDP across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

CIDP Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Chronic inflammatory demyelinating polyneuropathy (CIDP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company        Partner        Stage

1        IgPro20        CSL Behring        ICON Clinical Research        Phase 3

2        NPB-01        Nihon Pharmaceutical Co., Ltd       Phase 3

3        Efgartigimod PH20 SC        argenx                Phase 2

4        BIVV020        Sanofi                Phase 2

5        Fingolimod        Novartis Pharmaceuticals        Mitsubishi Tanabe Pharma Corporation        Phase 3

6        Rozanolixizumab        UCB Biopharma SRL        UCB Pharma        Phase 2

7        HYQVIA        Baxalta now part of Shire        Takeda        Phase 3

8        Immune Globulin IV         Grifols Therapeutics LLC   Phase 3

9        I10E             Laboratoire français de Fractionnement et de Biotechnologies Phase 3

10        Rituximab         Zenyaku Kogyo Co., Ltd.   Phase 2

11        NewGam        Octapharma                Phase 3

12        MD1003          MedDay Pharmaceuticals SA  Phase 2